Skip to main content
Alligator Bioscience logo

Alligator Bioscience — Investor Relations & Filings

Ticker · ATORX ISIN · SE0024173637 LEI · 549300E15VI0MB7LXV19 ST Manufacturing
Open in API
Filings indexed 610 across all filing types
Latest filing 2024-04-05 AGM Information
Country SE Sweden
Listing ST ATORX

About Alligator Bioscience

https://alligatorbioscience.se/en/

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Recent filings

Filing Released Lang Actions
Notice of annual general meeting in Alligator Bioscience AB
AGM Information Classification · 1% confidence The document is explicitly titled "NOTICE OF ANNUAL GENERAL MEETING IN ALLIGATOR BIOSCIENCE AB" and details the date, time, location, shareholder rights, proposed agenda items (including election of directors, approval of reports, and remuneration guidelines), and proposed resolutions for the meeting. This content is characteristic of materials distributed to shareholders in advance of an Annual General Meeting (AGM). Although it mentions the Annual Report and Remuneration Report, the primary purpose and structure of the document is the notice and associated proposals for the AGM itself. Therefore, the correct classification is AGM Information (AGM-R).
2024-04-05 English
Kallelse till årsstämma i Alligator Bioscience AB
AGM Information Classification · 1% confidence The document is titled "KALLELSE TILL ÅRSSTÄMMA I ALLIGATOR BIOSCIENCE AB" which translates to "NOTICE OF ANNUAL GENERAL MEETING IN ALLIGATOR BIOSCIENCE AB". The text details the date, time, location for the meeting, requirements for shareholder participation (registration, proxies), and presents a detailed proposed agenda (Förslag till Dagordning) including items like election of board members, approval of financial statements, and decisions on remuneration guidelines and stock option programs. These elements are characteristic of a formal notice and materials distributed for an Annual General Meeting (AGM). This aligns perfectly with the definition for AGM Information (AGM-R). Although it contains proposals that might be in a Proxy Statement (DEF 14A/PSI), the primary nature of the document is the official call and agenda for the AGM itself.
2024-04-05 Swedish
Alligator publishes supplementary prospectus
Report Publication Announcement Classification · 1% confidence The document is titled "ALLIGATOR PUBLISHES SUPPLEMENTARY PROSPECTUS" and explicitly states that it is a press release dated March 22, 2024. It discusses the preparation and approval of a Supplement Prospectus related to a Rights Issue, which supplements a previously registered Prospectus. Crucially, the document concludes by stating: "In accordance with article 2 k of the Prospectus Regulation this press release constitutes an **advertisement**." Furthermore, the document is relatively short (12,326 chars) and its primary function is to announce the availability of the Prospectuses and the right to withdraw applications, rather than being the full prospectus or a comprehensive financial report itself. According to Rule 2 ("THE 'MENU VS MEAL' RULE"), a short announcement regarding the publication or availability of a formal report/prospectus points towards a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since this document specifically announces the publication of a prospectus supplement related to a capital raising activity (Rights Issue), RPA is the most precise fit, as it announces the release of a key document. It is not the full 10-K, IR, or ER.
2024-03-22 English
Alligator offentliggör tilläggsprospekt
Capital/Financing Update Classification · 1% confidence The document is a press release from Alligator Bioscience AB announcing the publication of a 'Tilläggsprospekt' (Supplemental Prospectus) related to a previous offering. The text explicitly states that this press release is 'marknadsföring' (marketing) according to the Prospectus Regulation and directs investors to the actual Prospectus documents for investment decisions. Furthermore, the document ends with a section titled 'Bifogade filer' (Attached files) linking to the actual announcement PDF, which strongly suggests this text itself is the announcement of the report/prospectus, not the comprehensive report itself. Since it is an announcement regarding the publication of official offering/financing documents (Prospectus/Supplemental Prospectus), it relates to capital raising activities. The most fitting category for an announcement about a prospectus related to a rights issue/offering is 'Capital/Financing Update' (CAP). While it could potentially be an RPA if it were purely announcing the publication of a document without context, the core subject matter is the financing activity itself (the supplemental prospectus for the unit offering). Given the context of a prospectus being approved by Finansinspektionen (Swedish FSA) for a rights issue, CAP is the primary classification, although RPA is a close secondary consideration if the focus was solely on the act of publishing.
2024-03-22 Swedish
Annual Report (ESEF) 2023
Annual Report (ESEF) Classification · 1% confidence FY 2023
2024-03-21 Swedish
The subscription period in Alligator Bioscience’s rights issue begins today
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing the start of the subscription period for Alligator Bioscience AB's rights issue of shares and warrants. It details the terms, timetable, and references a Prospectus approved by the Swedish Financial Supervisory Authority. This type of announcement, focusing on fundraising, capital structure changes, and the initiation of a subscription period, aligns directly with the definition of a Capital/Financing Update. Although it mentions the Prospectus, the document itself is the announcement of the financing event, not the Prospectus or a general regulatory filing (RNS). Therefore, the most specific code is CAP.
2024-03-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.